Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SC 01009

Next Previous
Drug Profile

SC 01009

Alternative Names: Menstrual blood-derived mesenchymal stem cell therapy - Zhejiang Shengchuang Precision Medical Technology Co., Ltd; SC-01009; Uterine blood-derived mesenchymal stem cells - Zhejiang Shengchuang Precision Medical Technology

Latest Information Update: 03 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zhejiang Shengchuang Precision Medical Technology
  • Class Mesenchymal stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis

Most Recent Events

  • 26 Aug 2025 Zhejiang Shengchuang Precision Medical Technology has patent protection for menstrual blood mesenchymal stem cells (Zhejiang Shengchuang Precision Medical Technology website, August 2025)
  • 20 Aug 2025 Preclinical trials in Idiopathic pulmonary fibrosis in China (IV)
  • 20 Aug 2025 Zhejiang Shengchuang Precision Medical Technology plans a phase II trial for Idiopathic pulmonary fibrosis (Treatment experienced) in China (IV, ijnection) in August 2025 (NCT07131150)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top